Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 2 distinct examiners, ensuring that each case is reviewed by a different individual. The prosecution is also taking place in 2 distinct art units, which indicates that the company's pharmaceutical filings are technically diverse enough to be handled by different specialized groups. This distribution suggests a broad approach to securing intellectual property in the biotech sector.
The busiest examiner for this portfolio is CUTLIFF, YATE KAI RENE, who is responsible for 1 busiest examiner pending office action. With a total of 2 pending office actions, this examiner handles a significant portion of the company's current active cases. This concentration means that the examiner's feedback will be a major factor in the portfolio's overall progress. For a practitioner, managing 2 distinct examiners across 2 distinct art units requires a strategy that can accommodate different examining styles and procedural norms. The outcome of these 2 pending office actions will provide important insights into the company's standing within the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CUTLIFF, YATE KAI RENE | 1 | 79.9% | +24.2% |
| BRANDSEN, BENJAMIN MICHAEL | 1 | 61.9% | +20.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18684974 | AN IMPROVED PROCESS FOR THE PREPARATION OF N-ETHYL- A -METHYL-3-(TRIFLUOROMETHYL) PHENETHYLAMINE HYDROCHLORIDE | CUTLIFF, YATE KAI RENE | — |
| 18288402 | SOLID FORM OF 2-CHLORO-2'-DEOXY-ADENOSINE COMPLEX WITH HPßCD | BRANDSEN, BENJAMIN MICHAEL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18684974 | AN IMPROVED PROCESS FOR THE PREPARATION OF N-ETHYL- A -METHYL-3-(TRIFLUOROMETHYL) PHENETHYLAMINE HYDROCHLORIDE | CUTLIFF, YATE KAI RENE | — |
| 18288402 | SOLID FORM OF 2-CHLORO-2'-DEOXY-ADENOSINE COMPLEX WITH HPßCD | BRANDSEN, BENJAMIN MICHAEL | — |
| Art Unit | Apps |
|---|---|
| 1692 | 1 |
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18684974 | AN IMPROVED PROCESS FOR THE PREPARATION OF N-ETHYL- A -METHYL-3-(TRIFLUOROMETHYL) PHENETHYLAMINE HYDROCHLORIDE | CUTLIFF, YATE KAI RENE | 1692 | §102§103§112 | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18288402 | SOLID FORM OF 2-CHLORO-2'-DEOXY-ADENOSINE COMPLEX WITH HPßCD | BRANDSEN, BENJAMIN MICHAEL | 1693 | §103§112 | Final Rejection | — | Pending | Oct 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBIOPHORE INDIA PHARMACEUTICALS PVT. LTD. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Yate Kai Rene Cutliff has the most, with 1 of BIOPHORE INDIA PHARMACEUTICALS PVT. LTD.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.